Immediate Impact
66 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
2025 Standout
Works of Mallory Makowsky being referenced
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Mallory Makowsky | 105 | 19 | 28 | 125 | 45 | 4 | 162 | |
| Derek-Zhen Xu | 88 | 22 | 26 | 118 | 45 | 6 | 162 | |
| Marta Piqué‐Gili | 52 | 20 | 26 | 74 | 34 | 4 | 122 | |
| Magdalena Żotkiewicz | 60 | 56 | 29 | 80 | 37 | 6 | 137 | |
| Erik Ramon‐Gil | 49 | 22 | 24 | 69 | 34 | 5 | 120 | |
| Jordi Abril‐Fornaguera | 63 | 27 | 27 | 76 | 35 | 4 | 197 | |
| Yamil Alonso Lopez Chuken | 28 | 12 | 17 | 74 | 28 | 5 | 90 | |
| Iain Tan | 57 | 23 | 22 | 126 | 9 | 5 | 196 | |
| Joseph Hreiki | 70 | 43 | 19 | 58 | 21 | 6 | 147 | |
| Carmen Andreu-Oller | 33 | 10 | 39 | 72 | 13 | 2 | 122 | |
| Anne E. Borgman-Hagey | 35 | 11 | 22 | 96 | 48 | 7 | 117 |
All Works
Loading papers...